Cardiovascular Revascularization Medicine
Volume 8, Issue 3 , Pages 156-160 , July 2007

Predictive value of preintervention C-reactive protein on clinical outcome after directional coronary atherectomy followed by stent implantation

Received 16 January 2007 ,Revised 20 February 2007 ,Accepted 20 February 2007.

References 

  1. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol. 1999;34:1512–1521
  2. Toutouzas K, Colombo A, Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J. 2004;25:1679–1687
  3. Prati F, Di Mario C, Moussa I, Reimers B, Mallus MT, Parma A, et al. In-stent neointimal proliferation correlates with the amount of residual plaque burden outside the stent: an intravascular ultrasound study. Circulation. 1999;99:1011–1014
  4. Niccoli G, Testa L, Mongiardo R, Ricco A, Belloni F, Romagnoli E, et al. Directional atherectomy before stenting versus stenting alone in percutaneous coronary interventions: a meta-analysis. Int J Cardiol. 2006;112:178–183
  5. Simonton CA. Directional coronary atherectomy: optimal atherectomy trials and new combined strategies with coronary stents. Semin Interv Cardiol. 2000;5:193–198
  6. Mak KH, Faxon DP. Clinical studies on coronary revascularization in patients with type 2 diabetes. Eur Heart J. 2003;24:1087–1103
  7. Stankovic G, Colombo A, Bersin R, Popma J, Sharma S, Cannon LA, et al. Comparison of directional coronary atherectomy and stenting versus stenting alone for the treatment of de novo and restenotic coronary artery narrowing. Am J Cardiol. 2004;93:953–958
  8. Versaci F, Gaspardone A, Tomai F, Ribichini F, Russo P, Proietti I, et al. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol. 2002;40:1935–1942
  9. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part I. Circulation. 2003;107:2274–2279
  10. Sardella G, Accapezzato D, Di Roma A, Francavilla V, Di Russo C, Iannucci G, et al. Altered trafficking of CD8+ memory T cells after implantation of rapamycin-eluting stents in patients with coronary artery disease. Immunol Lett. 2005;96:85–91
  11. Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A, et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation. 2002;106:2649–2651
  12. Karha J, Bavry AA, Rajagopal V, Henderson MR, Ellis SG, Brener SJ. Relation of C-reactive protein level and long-term risk of death or myocardial infarction following percutaneous coronary intervention with a sirolimus-eluting stent. Am J Cardiol. 2006;98:616–618
  13. Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation. 2004;110:1747–1753
  14. Tanaka A, Shimada K, Sano T, Namba M, Sakamoto T, Nishida Y, et al. Multiple plaque rupture and C-reactive protein in acute myocardial infarction. J Am Coll Cardiol. 2005;45:1594–1599

PII: S1553-8389(07)00043-7

doi: 10.1016/j.carrev.2007.02.002

Cardiovascular Revascularization Medicine
Volume 8, Issue 3 , Pages 156-160 , July 2007

Article Tools

* Image Usage & Resolution